melagatran has been researched along with doxazosin in 2 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (doxazosin) | Trials (doxazosin) | Recent Studies (post-2010) (doxazosin) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 1,372 | 439 | 283 |
| Protein | Taxonomy | melagatran (IC50) | doxazosin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.544 | |
| Interstitial collagenase | Homo sapiens (human) | 5.749 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.748 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2.2155 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0034 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.544 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.688 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.368 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0007 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.188 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4022 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 2.2155 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
2 other study(ies) available for melagatran and doxazosin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |